cilostazol has been researched along with Coronary Restenosis in 55 studies
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Cilostazol has been reported to control neointimal proliferation after stenting." | 5.31 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0." | 3.84 | Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009) |
| " Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting." | 3.81 | Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004) |
| " Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model." | 3.79 | The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013) |
| "Treatment with cilostazol is likely a cost-saving or dominant strategy in patients with successful coronary bare metal stent implantation." | 2.72 | Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. ( Anderson, GT; Douglas, JS; Foster, JK; Jurkovitz, CT; Kolm, P; Murrah, NV; Parker, KM; Weintraub, WS; Zhang, Z, 2006) |
| "Cilostazol has properties that may reduce or avert in-stent coronary restenosis." | 2.71 | Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. ( Douglas, JS; Holmes, D; Weintraub, WS, 2003) |
| "Cilostazol has been used for antiplatelet therapy after coronary stent implantation, but the results are controversial." | 2.71 | RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. ( Chen, J; Du, Z; Ge, J; Han, Y; Jiang, H; Sun, B; Zhang, S, 2005) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.70 | Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002) |
| "In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation." | 2.49 | Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013) |
| "Cilostazol is a generic drug with antiplatelet and antiproliferative effects." | 2.48 | Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. ( Eisenberg, MJ; Friedland, SN; Shimony, A, 2012) |
| " There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0." | 2.48 | The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012) |
| "Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication." | 2.45 | A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. ( Dindyal, S; Kyriakides, C, 2009) |
| "Cilostazol is a phosphodiesterase III inhibitor with pharmacological effects that include vasodilation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth." | 2.43 | The vascular effects of cilostazol. ( Weintraub, WS, 2006) |
| "Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors." | 2.41 | Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001) |
| "Cilostazol has also been reported to inhibit smooth muscle cell proliferation in vitro and has been demonstrated in a clinical study to favorably alter plasma lipids: to decrease triglyceride and to increase HDL-cholesterol levels." | 2.41 | Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. ( Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M, 2001) |
| " The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up." | 1.48 | The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. ( Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018) |
| "6 months, major adverse cardiac and cerebrovascular events (MACCE) occurred in 43 patients (17." | 1.39 | Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013) |
| " At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly." | 1.34 | Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. ( Hong, EH; Kim, MY; Lee, MH; Oh, JM; Park, JE; Shin, WG, 2007) |
| "Cilostazol has been reported to control neointimal proliferation after stenting." | 1.31 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (54.55) | 29.6817 |
| 2010's | 25 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, Y | 1 |
| Feng, ZW | 1 |
| Li, XY | 1 |
| Hu, ZH | 1 |
| Xu, Q | 1 |
| Wang, Z | 1 |
| Cheng, JH | 1 |
| Shi, HT | 1 |
| Wang, QB | 1 |
| Wu, HY | 1 |
| Xie, XQ | 1 |
| Lv, QZ | 1 |
| Suh, JW | 1 |
| Lee, SP | 1 |
| Park, K | 1 |
| Kang, HJ | 1 |
| Koo, BK | 2 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 2 |
| Choi, DJ | 1 |
| Rha, SW | 2 |
| Bae, JH | 2 |
| Kwon, TG | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kim, HS | 4 |
| Lee, SW | 11 |
| Ahn, JM | 2 |
| Han, S | 2 |
| Park, GM | 2 |
| Cho, YR | 2 |
| Lee, WS | 2 |
| Jang, JY | 2 |
| Kwon, CH | 2 |
| Lee, JY | 4 |
| Kim, WJ | 4 |
| Kang, SJ | 4 |
| Kim, YH | 8 |
| Lee, CW | 8 |
| Kim, JJ | 5 |
| Park, SW | 8 |
| Park, SJ | 8 |
| Lee, HJ | 1 |
| Yu, CW | 2 |
| Hwang, HK | 1 |
| Choi, RK | 1 |
| Park, JS | 1 |
| Li, H | 1 |
| Ro, YM | 1 |
| Park, DW | 5 |
| Park, YK | 1 |
| Youn, YJ | 1 |
| Lee, JW | 1 |
| Ahn, SG | 1 |
| Lee, SH | 1 |
| Choi, H | 1 |
| Hong, YJ | 2 |
| Kwon, HM | 1 |
| Hong, MK | 6 |
| Jang, Y | 1 |
| Yoon, J | 1 |
| Guerra, E | 1 |
| Byrne, RA | 1 |
| Kastrati, A | 2 |
| Inoue, T | 3 |
| de Donato, G | 1 |
| Setacci, F | 1 |
| Mele, M | 1 |
| Giannace, G | 1 |
| Galzerano, G | 1 |
| Setacci, C | 1 |
| Zuliani Mauro, MF | 1 |
| Mangione, JA | 1 |
| Costa, JR | 1 |
| Costa, R | 1 |
| Piva E Mattos, LA | 1 |
| Staico, R | 1 |
| Feres, F | 1 |
| Siqueira, D | 1 |
| Sousa, A | 1 |
| Abizaid, A | 1 |
| Biondi-Zoccai, GG | 1 |
| Lotrionte, M | 1 |
| Anselmino, M | 1 |
| Moretti, C | 1 |
| Agostoni, P | 1 |
| Testa, L | 1 |
| Abbate, A | 1 |
| Cosgrave, J | 1 |
| Laudito, A | 1 |
| Trevi, GP | 1 |
| Sheiban, I | 1 |
| Dindyal, S | 1 |
| Kyriakides, C | 1 |
| Amasyali, B | 1 |
| Celik, T | 1 |
| Iyisoy, A | 1 |
| Kilic, A | 1 |
| Isik, E | 1 |
| Tamhane, U | 1 |
| Meier, P | 1 |
| Chetcuti, S | 1 |
| Chen, KY | 1 |
| Grossman, MP | 1 |
| Gurm, H | 1 |
| Jennings, DL | 1 |
| Kalus, JS | 1 |
| Chun, KJ | 2 |
| Yun, SC | 3 |
| Rhee, KS | 1 |
| Chae, JK | 1 |
| Ko, JK | 2 |
| Park, JH | 3 |
| Lee, JH | 3 |
| Choi, SW | 3 |
| Jeong, JO | 1 |
| Seong, IW | 3 |
| Jon, S | 1 |
| Cho, YH | 3 |
| Lee, NH | 3 |
| Kim, JH | 5 |
| Shin, WY | 1 |
| Lee, SJ | 1 |
| Hyon, MS | 1 |
| Bang, DW | 1 |
| Choi, YJ | 1 |
| Lee, BK | 2 |
| Lee, K | 1 |
| Park, HK | 1 |
| Park, CB | 1 |
| Lee, SG | 1 |
| Kim, MK | 1 |
| Park, KH | 2 |
| Park, WJ | 1 |
| Dihu, JB | 1 |
| Abudayyeh, I | 1 |
| Saudye, HA | 1 |
| Gurujal, R | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Friedland, SN | 1 |
| Eisenberg, MJ | 1 |
| Shimony, A | 1 |
| Hirayama, H | 1 |
| Wang, P | 1 |
| Zhou, S | 1 |
| Zhou, R | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| He, J | 1 |
| Ma, C | 1 |
| He, Y | 1 |
| Yang, J | 1 |
| Jeong, YH | 2 |
| Park, Y | 1 |
| Muse, WC | 1 |
| Kwon, TJ | 1 |
| Koh, JS | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Sakurai, R | 1 |
| Kaneda, H | 1 |
| Bonneau, HN | 1 |
| Nagai, R | 1 |
| Jang, JS | 1 |
| Jin, HY | 1 |
| Seo, JS | 1 |
| Yang, TH | 1 |
| Kim, DK | 2 |
| Kim, DS | 1 |
| Seol, SH | 1 |
| Kim, DI | 1 |
| Cho, KI | 1 |
| Kim, BH | 1 |
| Park, YH | 1 |
| Je, HG | 1 |
| Geng, DF | 1 |
| Liu, M | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 2 |
| Wang, JF | 1 |
| Jeong, MH | 2 |
| Kim, JM | 1 |
| Park, DS | 1 |
| Lim, KS | 1 |
| Lee, KH | 1 |
| Sim, DS | 1 |
| Yoon, HJ | 1 |
| Yoon, NS | 1 |
| Kim, KH | 2 |
| Park, HW | 1 |
| Ahn, Y | 2 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Kamishirado, H | 1 |
| Mizoguchi, K | 1 |
| Uchida, T | 2 |
| Nakata, T | 1 |
| Sakuma, M | 2 |
| Takayanagi, K | 1 |
| Morooka, S | 1 |
| Silber, S | 1 |
| Tsuchikane, E | 1 |
| Kobayashi, T | 2 |
| Takeda, Y | 1 |
| Otsuji, S | 1 |
| Sakurai, M | 1 |
| Awata, N | 1 |
| Douglas, JS | 6 |
| Weintraub, WS | 5 |
| Holmes, D | 1 |
| Mintz, GS | 1 |
| Song, JM | 1 |
| Han, KH | 2 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Foster, J | 2 |
| Culler, SD | 1 |
| Becker, ER | 1 |
| Parker, K | 2 |
| Zhang, Z | 2 |
| Kolm, P | 2 |
| Sekiguchi, M | 1 |
| Hoshizaki, H | 1 |
| Adachi, H | 1 |
| Ohshima, S | 1 |
| Taniguchi, K | 1 |
| Kurabayashi, M | 1 |
| Hashiguchi, M | 1 |
| Ohno, K | 1 |
| Nakazawa, R | 1 |
| Kishino, S | 1 |
| Mochizuki, M | 1 |
| Shiga, T | 1 |
| Imoto, Y | 1 |
| Ozeki, Y | 1 |
| Ozaki, Y | 1 |
| Hikichi, Y | 1 |
| Node, K | 1 |
| Conti, CR | 1 |
| Ge, J | 2 |
| Han, Y | 2 |
| Jiang, H | 1 |
| Sun, B | 1 |
| Chen, J | 1 |
| Zhang, S | 1 |
| Du, Z | 1 |
| Wang, S | 1 |
| Li, Y | 1 |
| Jing, Q | 1 |
| Ma, Y | 1 |
| Yang, G | 1 |
| Yu, H | 1 |
| Holmes, DR | 1 |
| Kereiakes, DJ | 1 |
| Grines, CL | 1 |
| Block, E | 1 |
| Ghazzal, ZM | 1 |
| Morris, DC | 1 |
| Liberman, H | 1 |
| Jurkovitz, C | 1 |
| Murrah, N | 1 |
| Hyde, P | 1 |
| Mancini, GB | 1 |
| Schömig, A | 1 |
| Wessely, R | 1 |
| Morishita, R | 1 |
| Ujiie, Y | 1 |
| Hirosaka, A | 1 |
| Mitsugi, M | 1 |
| Ohwada, T | 1 |
| Igarashi, M | 1 |
| Kijima, M | 1 |
| Komatsu, N | 1 |
| Hisa, S | 1 |
| Abe, Y | 1 |
| Tsuda, T | 1 |
| Yaoita, H | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Foster, JK | 1 |
| Jurkovitz, CT | 1 |
| Parker, KM | 1 |
| Murrah, NV | 1 |
| Anderson, GT | 1 |
| Hong, EH | 1 |
| Kim, MY | 1 |
| Park, JE | 1 |
| Lee, MH | 1 |
| Oh, JM | 1 |
| Shin, WG | 1 |
| Jang, S | 1 |
| Chi, HS | 1 |
| Jeong, JW | 1 |
| Ahn, TH | 1 |
| Kang, WC | 1 |
| Park, CG | 1 |
| Nam, CW | 1 |
| Hur, SH | 1 |
| Kim, KY | 1 |
| Oh, SK | 1 |
| El-Beyrouty, C | 1 |
| Spinler, SA | 1 |
| Liu, Y | 1 |
| Shakur, Y | 1 |
| Yoshitake, M | 1 |
| Kambayashi Ji, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724] | Phase 4 | 630 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927] | Phase 4 | 486 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for cilostazol and Coronary Restenosis
| Article | Year |
|---|---|
Pharmacological inhibition of coronary restenosis: systemic and local approaches.
Topics: Anti-Bacterial Agents; Antioxidants; Cilostazol; Coronary Restenosis; Drug Delivery Systems; Drug-El | 2014 |
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
Topics: Cardiovascular Agents; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Endovascular Proced | 2017 |
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coronary Restenosis; Humans; Platelet Aggregation Inhibi | 2008 |
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
Topics: Angioplasty; Arterial Occlusive Diseases; Cilostazol; Clinical Trials as Topic; Coronary Restenosis; | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.
Topics: Aspirin; Cilostazol; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting | 2010 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coronary Restenosis; Global Health; Humans; Incidence; M | 2012 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art | 2012 |
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin | 2013 |
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].
Topics: Brachytherapy; Cell Division; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coated Materials, B | 2002 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Role of adjunct pharmacologic therapy in the era of drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Restenosis; Hu | 2005 |
A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.
Topics: Cilostazol; Coronary Restenosis; Humans; Muscle, Smooth, Vascular; Platelet Aggregation Inhibitors; | 2005 |
The vascular effects of cilostazol.
Topics: Animals; Cell Proliferation; Cilostazol; Coronary Restenosis; Endothelium, Vascular; Humans; Lipids; | 2006 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease | 2007 |
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cilostazol; Coronary Disease; Coronary Restenosis; | 2001 |
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Oc | 2001 |
23 trials available for cilostazol and Coronary Restenosis
| Article | Year |
|---|---|
The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.
Topics: Aged; Antineoplastic Agents; Cilostazol; Coronary Angiography; Coronary Restenosis; Drug Therapy, Co | 2017 |
Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
Topics: Cilostazol; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relati | 2013 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; D | 2014 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete | 2010 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M | 2011 |
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy | 2002 |
Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
Topics: Adolescent; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis; Double-Blind Method; Fem | 2003 |
Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.
Topics: Angioplasty, Balloon, Coronary; Chemoprevention; Cilostazol; Coronary Restenosis; Cost-Benefit Analy | 2004 |
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.
Topics: Aged; Cilostazol; Coronary Restenosis; Coronary Stenosis; Equipment Design; Female; Follow-Up Studie | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Cilostazol; Coronary Angiography; Coronary Artery Disease | 2004 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; China; Cilostazol; Coronary Angiography; Co | 2005 |
Cilostazol improves long-term outcomes after coronary stent implantation.
Topics: Cilostazol; Coronary Restenosis; Coronary Stenosis; Humans; Platelet Aggregation Inhibitors; Prospec | 2005 |
Coronary stent restenosis in patients treated with cilostazol.
Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human | 2005 |
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; | 2006 |
Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
Topics: Adult; Cilostazol; Coronary Restenosis; Coronary Stenosis; Cost-Benefit Analysis; Double-Blind Metho | 2006 |
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
Topics: Aspirin; Biomarkers; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Resteno | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
14 other studies available for cilostazol and Coronary Restenosis
| Article | Year |
|---|---|
The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.
Topics: Aged; Asian People; Aspirin; China; Cilostazol; Clopidogrel; Coronary Restenosis; Data Interpretatio | 2018 |
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb | 2013 |
[Cilostazol].
Topics: Cilostazol; Coronary Restenosis; Humans; Percutaneous Coronary Intervention; Phosphodiesterase 3 Inh | 2016 |
Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Res | 2010 |
Cilostazol: a potential therapeutic option to prevent in-stent restenosis.
Topics: Cilostazol; Coronary Restenosis; Drug-Eluting Stents; Humans; Prosthesis Failure; Tetrazoles | 2011 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
[Cilostazol].
Topics: Animals; Cilostazol; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Stents; Tetrazole | 2011 |
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl | 2012 |
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor | 2013 |
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).
Topics: Aged; Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Cilostazol; Combined Modality The | 2002 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Not just another restenosis trial.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Combined Modality Therapy; Coronary Artery Disease; Coro | 2004 |
Prevention of restenosis by systemic drug therapy: back to the future?
Topics: Cilostazol; Controlled Clinical Trials as Topic; Coronary Restenosis; Double-Blind Method; Drug Admi | 2005 |
Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.
Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Cilostazol; Coronary Angiography; Coronar | 2007 |